Abstract
In the present study the action of various cytokines as regulators of human melanocyte growth and differentiation was examined in vitro. Primary melanocyte cultures were obtained in complete medium free of 12-O-tetradecanoylphorbol-13-acetate or serum. First passage melanocytes were treated with various concentrations of recombinant tumour necrosis factor alpha and beta (rTNF-alpha, rTNF-beta), as well as with various recombinant interleukins (rIL-1a, rIL-1b, rIL-2, rIL-3, rIL-4 and rIL-6) for 6 days in complete medium and for 6 and 12 days in a mitogen-reduced medium variant. The 4-methylumbelliferyl heptanoate fluorometric microassay and Ki-67 staining were used for assessing cell proliferation, and the immunophenotype was evaluated using various monoclonal antibodies. Melanocyte proliferation in complete medium was inhibited by rTNF-alpha (−24%), rTNF-beta (−17%), rIL-1a (−21%), rIL-1b (−18%) and rIL-6 (−29%); in contrast, rIL-2, rIL-3 and rIL-4 had no antiproliferative effect. Measurements of Ki-67-positive nuclei confirmed these results. In the reduced medium variant, none of the above cytokines inhibited melanocyte proliferation. Recombinant TNF-alpha and rTNF-beta markedly reduced the expression of the pigment cell-associated antigens HMB-45 and K.1.2, and they enhanced the expression of VLA-2, ICAM-1 and HLA class I antigens and strongly induced HLA-DR. Similar changes were induced by rIL-1a, rIL-b and rIL-6, and rIL-2 decreased the expression of HLA class I antigens and of ICAM-1. In conclusion, several cytokines inhibited the growth and modulated the phenotype of melanocytes in vitro. Since these cytokines are major mediators of inflammatory processes, they may cause the pigmentary alterations seen after cutaneous inflammatory processes.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Abdel-Naser MB, Krüger-Krasagakes S, Krasagakis K, Gollnick H, Orfanos CE (1994) Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo. Pigment Cell Res 7: 1–8
Al Badri AM, Foulis AK, Todd PM, Gariouch JJ, Gudgeon JE, Stewart DG, Gracie DG, Goudie RB (1993) Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo. J Pathol 169: 203–206
Ansel J, Perry P, Brown J, Damm D, Phan T, Hart C, Luger T, Hefeneider S (1990) Cytokine modulation of keratinocyte cytokines. J Invest Dermatol 94: 101S-107S
Bochner BS, Charlesworth EN, Lichtenstein LM, Derse CP, Gillis S, Dinarello CA, Schleimer RP (1990) Interleukin-1 is released at sites of human cutaneous allergic reactions. J Allergy Clin Immunol 86: 830–839
Brüggen J, Sorg C (1983) Detection of phenotypic differences on human malignant melanoma lines and their variant sublines with monoclonal antibodies. Cancer Immunol Immunother 15: 200–205
Cordell JL, Falini B, Erber WN, Ghosh A, Zainalabideen A, MacDonald S, Pulford KAF, Stein H, Masony DY (1984) Immunoenzymatic labelling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP-complexes). J Histochem Cytochem 32: 219–229
Detmar M, Orfanos CE (1990) Tumor necrosis factor-alpha inhibits cell proliferation and induces class II antigens and cell adhesion molecules in cultured normal human keratinocytes in vitro. Arch Dermatol Res 282: 238–245
Detmar M, Tenorio S, Hettmannsperger U, Ruszczak R, Orfanos CE (1992) Cytokine regulation of proliferation and ICAM-1 expression of human dermal microvascular endothelial cells in vitro. J Invest Dermatol 98: 147–153
Furue M, Ohtsuki M, Ogata F, Ishibashi Y (1991) Responsiveness to interleukin 4 and interleukin 2 of peripheral blood mononuclear cells in atopic dermatitis. J Invest Dermatol 96: 468–472
Gerdes J, Schwab K, Lemke H, Stein H (1983) Production of mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer 31: 13–20
Gilchrest BA, Vrabel MA, Flynn E, Szabo G (1984) Selective cultivation of human melanocytes from newborn and adult epidermis. J Invest Dermatol 83: 370–376
Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA (1986) Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 123: 195–203
Halaban R, Ghosh S, Baird A (1987) bFGF is the putative natural growth factor for human melanocytes. In Vitro 23: 47–52
Herlyn M, Kath R, Williams N, Valyi-Nagy I, Rodeck U (1990) Growth-regulatory factors for normal, premalignant and malignant human cells in vitro. Adv Cancer Res 54: 213–234
Kirnbauer R, Charvat B, Schauer K, Köck A, Urbanski A, Forster E, Neuner P, Assmann I, Luger TA, Schwarz T (1992) Modulation of intercellular adhesion molecule-1 expression on human melanocytes and melanoma cells: evidence for regulatory role of IL-6, IL-7, TNF-beta and UVB light. J Invest Dermatol 98: 320–326
Klein CE, Steinmayer T, Kaufmann D, Weber L, Bröcker EB (1991) Identification of a melanoma progression antigen as integrin VLA-2. J Invest Dermatol 96: 281–284
Krasagakis K, Garbe C, Krüger S, Orfanos CE (1991) Effects of interferons on cultured human melanocytes in vitro: interferon-beta but not -alpha or -gamma inhibit proliferation and all interferons significantly modulate the cell phenotype. J Invest Dermatol 97: 364–372
Krüger-Krasagakes S, Krasagakis K, Garbe C, Diamantstein T (1995) Production of cytokines by human melanoma cells and melanocytes. Recent Results Cancer Res (in press)
Lampson LA, Levy R (1980) The populations of Ia-like molecules on a human B cell line. J Immunol 125: 293–299
Malissen B, Rebai N, Liabeuf A, Mawas C (1982) Human cytotoxic T cell structures associated with expression of cytolysis I. Analysis at the clonal level of the cytolysis-inhibiting effect of 7 monoclonal antibodies. Eur J Immunol 12: 739–747
Nordlund JJ, Amornsiripanitch S, Rheins LA, Abdel-Malek ZA, Boissy RE, Bell M (1988) Role of melanocyte in epidermal inflammatory and immune responses. Pigment Cell Res [Suppl] 1: 101–112
Plaisance S, Rubinstein E, Alileche A, Han DS, Sahraoui Y, Mingari MC, Bellomo R, Rimoldi D, Colombo MP, Jasmin C, Carrel S, Azzarone B (1993) Human melanoma cells express a functional interleukin-2 receptor. Int J Cancer 55: 164–170
Rothlein R, Dustin MC, Marlin SD, Springer TA (1986) A human intercellular adhesion molecule (ICAM-1) distinct from LFA-1. J Immunol 137: 1270–1275
Sauder DN, Stanulis-Praeger BM, Gilchrest BA (1988) Autocrine growth stimulation of human keratinocytes by epidermal cell-derived thymocyte activating factor: implications for skin aging. Arch Dermatol Res 280: 71–76
Schaumburg-Lever G, Metzler G, Kaiserling E (1991) Ultrastructural localization of HMB-45 binding sites. J Cutan Pathol 18: 432–435
Schmidt JA, Mizel SB, Cohen D, Green I (1982) Interleukin 1, a potential regulator of fibroblast proliferation. J Immunol 128: 2177–2182
Smoller BR, Hsu A, Krueger J (1990) HMB-45 monoclonal antibody recognizes and inducible and reversible melanocyte cytoplasmic protein. J Cutan Pathol 18: 315–322
Suter L, Brüggen J, Bröcker EB, Sorg C (1985) A tumor-associated antigen expressed in melanoma cells with lower malignant potential. Int J Cancer 35: 787–791
Swope VB, Abdel-Malek Z, Kassem LM, Nordlund JJ (1991) Interleukins 1a and 6 and tumor necrosis factor-a are paracrine inhibitors of human melanocyte proliferation and melanogenesis. J Invest Dermatol 96: 180–185
Thestrup-Pedersen K, Larsen CS, Kristensen M, Zachariae C (1990) Interleukin-1 release from peripheral blood monocytes and soluble interleukin-2 and CD8 receptors in serum from patients with atopic dermatitis. Acta Derm Venereol 70: 395–399
Tsujisaki M, Igarashi M, Sakaguchi K, Eisinger M, Herlyn M, Ferrone S (1987) Immunochemical and functional analysis of HLA class II antigens induced by recombinant immune interferon on normal epidermal melanocytes. J Immunol 138: 1310–1316
Yohn JJ, Critelli M, Lyons MB, Norris DA (1990) Modulation of melanocyte intercellular adhesion molecule-1 by immune cytokines. J Invest Dermatol 95: 233–237
Zouboulis ChC, Garbe C, Krasagakis K, Krüger S, Orfanos CE (1991) A fluorometric rapid microassay to identify antiproliferative compounds for human melanoma cells in vitro. Melanoma Res 1: 91–95
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Krasagakis, K., Garbe, C., Eberle, J. et al. Tumour necrosis factors and several interleukins inhibit the growth and modulate the antigen expression of normal human melanocytes in vitro. Arch Dermatol Res 287, 259–265 (1995). https://doi.org/10.1007/BF01105076
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF01105076